Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial

The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Transl Med
Autors principals: Xu, Xiaowei, Jiang, Wanli, Chen, Lijun, Xu, Zhenyu, Zhang, Qiang, Zhu, Mengfei, Ye, Peng, Li, Hang, Yu, Liang, Zhou, Xiaoyang, Zhou, Chenliang, Chen, Xiaobei, Zheng, Xiaoqin, Xu, Kaijin, Cai, Hongliu, Zheng, Shufa, Jiang, Wubian, Wu, Xiaojun, Li, Dong, Chen, Lu, Luo, Qingqing, Wang, Yingyan, Qu, Jingjing, Li, Yifei, Zheng, Wendi, Jiang, Yingan, Tang, Lingling, Xiang, Charlie, Li, Lanjuan
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839959/
https://ncbi.nlm.nih.gov/pubmed/33634996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.297
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars